Epimmune Inc. develops novel vaccines for infectious diseases and cancer, building on the field of T-cell recognition and activation.
Value
Total number of shares outstanding as of July 11, 2000 7,340,000
Price of each share of common stock on July 11, 2000 5.97
Aggregate market value as of July 11, 2000 $43,819,800
Performance Record
For year ended Dec. 31, in millions, except per-share data
1999 1998 1997
Operating revenues $4.2 $3.7 $5.1
Net income (loss) $(8.3) $(21.5) $(14.4)
Net income (loss) per share $(1.56) $(4.48) $(3.92)
Total assets $12.7 $21.0 $28.1
Directors
Howard E. Greene Jr., 57, is a founder and served as director since its inception. He was elected as chairman in January 1989 and served as president from July 1987 to January 1989. He is also a director of Amylin Pharmaceuticals, Biosite Diagnostics and International Biotechnology Trust plc.
William T. Comer, 64, served as director since January 1994. Since January 2000, he served as an advisor to several pharmaceutical and biotech companies.
Michael G. Grey, 47, served as director since July 1999. Since January 1999, he has been president and CEO of Trega Biosciences, Inc. He is also a director of Cortex Pharmacueticals and ChemNavigator.com.
John P. McKearn, 46, has been with G.D. Searle & Co., now Pharmacia, since 1987. Since August 1999, he served as vice president of discovery research for Pharmacia.
Deborah A. Schueren, 36, has served as president, CEO and CFO and director since July 1999.
